Obesity Stock Plays That Stand Out From the Crowd
When it comes to diseases that kill, obesity probably doesn’t spring to mind ahead of a disease like cancer, but a closer look shows that obesity takes more lives than one might think. Since the...
View ArticleClik here to view.
Gilead’s Sovaldi Awarded Breakthrough Designation
A number of drugs currently in development were approved for a “breakthrough therapy” designation from the Food and Drug Administration this past year, with Gilead Sciences’ (NASDAQ:GILD) Sovaldi, a...
View ArticleClik here to view.
Is Johnson & Johnson a Rare Big Pharma Opportunity?
Johnson & Johnson (NYSE:JNJ) is a rare big pharma seeing long-term consistent growth unlike its peers Eli Lilly (NYSE:LLY) and Pfizer (NYSE:PFE). Given valuations seen with the likes of Gilead...
View ArticleClik here to view.
Intercept’s Fibrosis Success Gives Galectin High Hope
Intercept Pharmaceuticals (NASDAQ:ICPT) served as a catalyst for biotechnology firms in the fibrosis space on January 9. That’s when the company said that its Phase 2 trial of obeticholic acid (or,...
View ArticleClik here to view.
Whisper Number: What Will Gilead’s Shares Do Post-Earnings?
Gilead Sciences (NASDAQ:GILD) is expected to report earnings on Tuesday, February 4. The whisper number is $0.55, five cents ahead of the analysts’ estimate. Whispers range from a low of $0.50 to a...
View ArticleClik here to view.
3 Healthcare Stocks Making News: Soligenix, Pharmacyclics, & Gilead
As the healthcare sector continues to produce awe-inspiring returns, investors may want to consider three stocks that appear especially primed for growth after promising news. Those three stocks are...
View ArticleClik here to view.
Forget Rent: The Cost of These 5 New Drugs Is Too Damn High
Source: Thinkstock Disclaimer: The following list was composed using the FDA’s list of drugs approved in 2013 and 2014 (so far.) We were only able to rate the drugs we currently have pricing data for,...
View ArticleClik here to view.
Big Pharma Needs Growth: Two Severely Undervalued Companies Ripe for a Takeover
Source: Thinkstock At any given moment, there are literally hundreds of severely undervalued companies that are ripe for takeovers. In this article, I will focus on the pharmaceutical industry, where...
View ArticleClik here to view.
Does the Gilead Whisper Number Indicate Earnings Confidence?
Gilead Sciences (NASDAQ:GILD) is expected to report earnings on Wednesday. The whisper number is $1.73, 6 cents behind the analysts’ estimate and showing no confidence from investors. Gilead a 67...
View ArticleClik here to view.
3 Healthcare Stocks to Keep Your Portfolio Feeling Good
Source: Thinkstock The world is not getting any younger. Over the coming decades, the United States and other developed nations will see their populations turn increasingly gray. This change in...
View Article
